| Company/Division name | Thermo Fisher Scientific Inc. |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 500 |
| Year reshoring announced: | 2020 |
| Year reshoring implemented or to be implemented: | 2022 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 500 |
| City reshored to: | Greenville |
| State(s) reshored to: | NC |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | medicines, therapies, and vaccines |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption risk/Natural disaster risk/Political instability |
| What domestic positive factors made reshoring more attractive? | Lead time/Time to market, Proximity to customers/market |
